A Dose Escalation, Single and Multiple Dose, Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Evocalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Kyowa Kirin
- 16 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Apr 2014 New trial record